Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Mateos, M.V. (María Victoria); Hernandez, J.M. (J. M.); Hernandez, M.T. (Miguel Teodoro); Gutierrez, N.C. (Norma C.); Palomera, L. (Luis); Fuertes, M. (M.); Garcia-Sanchez, P. (P.); Lahuerta, J.J. (Juan José); Rubia, J. (Javier) de la; Terol, M.J. (María José); Sureda-Balari, A. M. (Anna Maria); Bargay, J. (Joan); Ribas, P. (Paz); Alegre, A. (A.); Arriba, F. (Felipe) de; Oriol, A. (Albert); Carrera, D. (D,); Garcia-Laraña, J. (J.); García-Sanz, R. (Ramón); Bladé, J. (Joan); Prosper-Cardoso, F. (Felipe); Mateo, G. (Gemma); Esseltine, D.L. (D. L.); Velde, H. (Helgi) van de; San-Miguel, J.F. (Jesús F.)

Full metadata record

Appears in Collections:

DA - CIMA - Hemato-oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Medicina regenerativa - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista

DC Field	Value	Language
dc.creator	Mateos, M.V. (María Victoria)	-
dc.creator	Hernandez, J.M. (J. M.)	-
dc.creator	Hernandez, M.T. (Miguel Teodoro)	-
dc.creator	Gutierrez, N.C. (Norma C.)	-
dc.creator	Palomera, L. (Luis)	-
dc.creator	Fuertes, M. (M.)	-
dc.creator	Garcia-Sanchez, P. (P.)	-
dc.creator	Lahuerta, J.J. (Juan José)	-
dc.creator	Rubia, J. (Javier) de la	-
dc.creator	Terol, M.J. (María José)	-
dc.creator	Sureda-Balari, A. M. (Anna Maria)	-
dc.creator	Bargay, J. (Joan)	-
dc.creator	Ribas, P. (Paz)	-
dc.creator	Alegre, A. (A.)	-
dc.creator	Arriba, F. (Felipe) de	-
dc.creator	Oriol, A. (Albert)	-
dc.creator	Carrera, D. (D,)	-
dc.creator	Garcia-Laraña, J. (J.)	-
dc.creator	García-Sanz, R. (Ramón)	-
dc.creator	Bladé, J. (Joan)	-
dc.creator	Prosper-Cardoso, F. (Felipe)	-
dc.creator	Mateo, G. (Gemma)	-
dc.creator	Esseltine, D.L. (D. L.)	-
dc.creator	Velde, H. (Helgi) van de	-
dc.creator	San-Miguel, J.F. (Jesús F.)	-
dc.date.accessioned	2011-04-20T14:10:42Z	-
dc.date.available	2011-04-20T14:10:42Z	-
dc.date.issued	2008	-
dc.identifier.citation	Mateos, M.-V., Hernández. J. M., Hernández, M. T., Gutiérrez, N. C. et al Haematologica 2008; 93(4): 560-565	es_ES
dc.identifier.issn	0390-6078	-
dc.identifier.uri	https://hdl.handle.net/10171/17831	-
dc.description.abstract	New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple myeloma are required. One strategy is to combine melphalan and prednisone with novel agents. We previously reported an 89% response rate, including 32% complete responses and 11% near complete responses, in our phase 1/2 study of bortezomib plus melphalan and prednisone (VMP) in 60 newly diagnosed multiple myeloma patients with a median age of 75 years. Here, we report updated time-to-events data and the impact of poor prognosis factors on outcome.	es_ES
dc.language.iso	eng	es_ES
dc.publisher	Fondazione Ferrata Storti	es_ES
dc.rights	info:eu-repo/semantics/openAccess	es_ES
dc.subject	Materias Investigacion::Ciencias de la Salud::Oncología	es_ES
dc.title	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression	es_ES
dc.type	info:eu-repo/semantics/article	es_ES
dc.relation.publisherversion	http://www.haematologica.org	es_ES